New study sheds light on how diabetes causes heart failure. Methylglyoxal (MG) is a glycolysis byproduct which is accelerated under diabetic conditions, modifies the cardiac myofilament more in diabetic heart failure patients.
- Patients with diabetes are more likely to develop heart failure
- Methylglyoxal (MG) is a glycolysis byproduct which is accelerated under diabetic conditions
- MG builds up in heart cells during diabetes, gums up the myofilaments and affects heart muscle contraction
- Therefore, identification of this approach may be a key early step in understanding how diabetes induces heart failure
Read More..
The study from the lab of Jonathan A. Kirk, Ph.D., is published in the American Society for Clinical Investigation journal JCI Insight. Dr. Kirk is an assistant professor in the Department of Cell and Molecular Physiology of Loyola University Chicago Stritch School of Medicine.
In a healthy heart, microscopic lattice-like structures called myofilaments cause heart muscle cells to contract. The cells work in concert to make the heart contract and relax with each beat.
In patients suffering from heart failure, heart muscle cells become weaker, and consequently, the heart does not pump enough blood to meet the body's needs. The patient experiences symptoms such as shortness of breath, fatigue, and swelling in the legs. Heart failure ultimately can be fatal.
Details of the Study
The research team examined heart tissue from three groups:
- People without heart failure
- People with heart failure who also had diabetes
- People with heart failure who did not have diabetes
Findings of the Study
The research team further found that the modifications caused by methylglyoxal weakened heart muscle cells by interfering with how the molecular motor works.
"This little molecule, methylglyoxal, builds up in heart cells during diabetes and gums up the myofilaments so they cannot contract as well," said lead author Maria Papadaki, Ph.D., a post-doctoral fellow at Loyola University Chicago Stritch School of Medicine.
The findings suggest a new approach to treating patients with diabetes who are at risk of developing heart failure. This approach involves developing drugs that would counter the effects of methylglyoxal by fine-tuning the myofilament motors.
Dr. Kirk speculates that the effects of methylglyoxal, as identified in the study, may be a key early step in how diabetes induces heart failure. This discovery could provide an effective therapeutic target for preventing heart failure in the growing population of diabetics.
Source-Eurekalert